ABT-199 - BCL-2 inhibitor. CAS# 1257044-40-8 Catalog No.:M60075-10S 5 µM in vitro and

5 µM in vitro and in cellular assays

PHF8 at IC50 ~0

20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H

is a potent small molecule that can promote chondrocyte differentiation of human mesenchymal stem cells/MSCs (EC50 = 100 nM)

cell-based screening using primary human hepatocytes

ABT-199 - BCL-2 inhibitor. CAS# 1257044-40-8 Catalog No.:M60075-10S 5 µM in vitro andABT 199, CAS No. 1257044 40 8, is a highly potent, selective, and orally bioavailable BCL 2 inhibitor. ABT 199 has picomolar affinity for BCL 2 (Ki < 0. 010 nM) and > 1000 folds selectivity over BCL XL (Ki = 48 nM) and BCL W (Ki = 245 nM). Therefore, ABT 199 is a much improved lead compound over the original ABT 263 (navitoclax) to avoid thrombocytopenia caused by BCL XL inhibition. ABT 199s cell killing effect is selective and mechanism dependent. It